Company Overview
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.07.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +124.91% |
| 6 Months: | +98.96% |
| 3 Months: | +18.02% |
| 1 Month: | +28.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)65.22 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ELVN Enliven Therapeutics, Inc. R2K | 51.73 | -31.54 | $3.15B | 0.00% | -26.04% | -26.64% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -4.19M | -5.56M | -6.88M | -7.35M | -10.30M | -12.49M | -10.28M | -13.17M | -13.66M | -8.68M | -9.02M | -10.93M | -16.42M | -20.13M | -24.25M | -25.99M | -24.60M | -27.07M | -31.69M | -28.58M | -25.10M | -27.82M |
| Net Income | -4.19M | -5.40M | -6.62M | -7.21M | -10.20M | -12.42M | -10.26M | -13.16M | -13.65M | -8.67M | -8.89M | -10.55M | -14.72M | -16.72M | -20.77M | -22.74M | -19.95M | -23.16M | -28.54M | -25.34M | -20.15M | -23.63M |
| Diluted EPS | - | - | - | - | - | - | - | -0.74 | -0.74 | -3.01 | -2.86 | -3.27 | -0.80 | -0.41 | -0.51 | -0.54 | -0.41 | -0.48 | -0.57 | -0.49 | -0.32 | -0.38 |
| R&D Expense | 3.56M | 4.37M | 5.14M | 5.79M | 7.87M | 9.53M | 7.12M | 10.07M | 10.40M | 7.06M | 7.94M | 7.83M | 11.88M | 15.18M | 19.61M | 19.97M | 18.83M | 21.26M | 24.89M | 21.49M | 18.23M | 20.69M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income | -24.12M | -41.70M | -51.44M | -38.79M | -83.53M | -104.55M | -119.66M |
| Net Income | -23.46M | -41.36M | -51.38M | -37.66M | -71.58M | -89.02M | -103.69M |
| Diluted EPS | - | - | -2.37 | -12.05 | -2.01 | -1.89 | -1.83 |
| R&D Expense | 19.01M | 32.15M | 38.44M | 31.02M | 64.57M | 80.78M | 85.86M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 33.30M | 90.84M | 93.65M | 83.30M | 271.87M | 325.76M | 476.17M |
| Total Equity | -26.32M | -48.85M | 84.44M | -42.89M | -76.83M | 245.91M | 309.85M | 459.60M |
| Cash & Equivalents | - | 4.94M | 47.70M | 48.31M | 75.54M | 100.14M | 124.12M | 98.90M |
| Total Liabilities | - | 4.38M | 6.41M | 7.62M | 10.37M | 25.96M | 15.91M | 16.57M |
| Current Liabilities | - | 4.20M | 6.25M | 7.21M | 9.71M | 25.89M | 15.91M | 16.57M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.88M | -37.40M | -46.77M | -32.08M | -61.27M | -73.19M | -70.30M |
| Investing Cash Flow | -24.06M | -16.72M | -1.63M | -612.00K | -148.41M | -36.00M | -173.84M |
| Financing Cash Flow | 43.58M | 96.88M | 49.10M | -1.80M | 234.29M | 133.16M | 218.87M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 48.0% | -49.0% | 119.8% | 49.0% | -29.1% | -28.7% | -22.6% |
| ROCE % | -82.9% | -49.3% | -59.5% | -52.7% | -34.0% | -33.7% | -26.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Orbimed Advisors LLC. | 13.07% | 7.96M | $407.29M |
| 2 | FMR, LLC | 11.21% | 6.83M | $349.45M |
| 3 | Polar Capital Holdings PLC | 8.32% | 5.07M | $259.22M |
| 4 | Blackrock Inc. | 6.05% | 3.68M | $188.55M |
| 5 | Commodore Capital Lp | 5.38% | 3.27M | $167.58M |
| 6 | Vestal Point Capital, LP | 5.34% | 3.25M | $166.30M |
| 7 | Bellevue Group AG | 3.81% | 2.32M | $118.76M |
| 8 | Vanguard Capital Management LLC | 3.56% | 2.17M | $110.94M |
| 9 | Fairmount Funds Management LLC | 3.05% | 1.86M | $94.95M |
| 10 | Citadel Advisors Llc | 2.86% | 1.74M | $89.24M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELVN
Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value Lags - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQSmUyaExTdlp0YzVEQUhncjVoeTNiRTR6cDJUalY2WUdwMk9KRUF6bGpMMk14aWlUU3Bud2FWbzFFaGRCRWhsMUdhZUtTWVg0bHlfVkZMVm5HZGF2dVJTemQ0RGFJSExrM3RnV3BQdzRMVDJRNWNnYkdRVFdNb3I0NEx0eFZsb3VyY1pIOD…
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxPS1Z3MFcxSnhhc0tZaTZoT1RSSjRpay05ZS1weEdETjlpRUxHUWQ0MjhGZFRRYkYzNnNwMXpNLWt5eEo1Mks0Vk14b1IzZm10UjY2LTh6WXJtV1ZCYVVqb1VQaWFHSVRGNWh6a3hVYlRTaXRvZUdrRl9FZmJWSlExWkUwTjZ6S2tNOUVuUj…
Enliven Therapeutics (ELVN) director sells 10,000 shares under 10b5-1 plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPR09OeG11WXBiOUdaN1pKeTN6cXVuSTcxcGE2X25oakV2VGJTMjA5VGVXTHh0SnFhQU9YeTFNWHNJeDZJem5Bdk9GVzgxclVDM254YjRaVmRNbUNqVUFvd1pveWN1ZEU3N3FxaExjcFlQcGF5Z2NtQTlKalVQSnd1QUtGRHAyc3ZodlhpaG…
Enliven Therapeutics (ELVN) Fell Out Of Russell Indexes, But Is The Valuation Already Rich? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxOSHFOV2ZmbGlpa3ZpTXZ2UG5oUWJVRDNuVjg3dVNRSEhJMnA2aGVFd3QtNjk5cHB1UUtZb0NnMG40b1Rfam9zcnQ4WTMyTmVJelRka2FaWTN6dFlZWDB3TzNfd1ZUYUNXY290ZlJvOEFMY25qbUQ0ZVBnOE85bjh5X3IxX3NqTUFGYm10Zz…
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxNdmpYclBULW9jVzJzaFFvclFmaXFOcmlZZE01QUNXNnM0YTUtSGxQOTRqcVY2XzJXZnFkdVFpc1d0b09QNFVkSDhEMHctMzZ6R0NBSWR5SkJ2MV9KMHNqbWJNdkM0Qi1GZWZrYm5HYWdNcEZWSkdKM3N0ZkdJVDNDR2FZUE9FZlVDeDdXQW…
ELVN Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5LMG05TTd1YlEwYVR3c3Vpbk1LYy1udnNOQXJMX1VkQ0R6c2lxMkdKUDBzWkVqVDlKMGg2RFcxMmRBemExSXBpWnlSel81UGZUckx6X0JhaG1SRmlERnZCNEV5VHZTNmloTHFzMFU3UmdFWHNpbFBJU25B?oc=5" target="_blank">ELV…
ELVN — Frequently Asked Questions
What is the current share price of Enliven Therapeutics, Inc. (ELVN)?
As of 2026-07-14 21:23 PDT, Enliven Therapeutics, Inc. (ELVN) trades at $51.73 on NasdaqGS. Its 52-week range is $15.14 to $52.18.
What is the market capitalisation of ELVN?
Enliven Therapeutics, Inc. (ELVN) has a market capitalisation of $3.15B on NasdaqGS.
What is the P/E ratio of ELVN?
ELVN trades at a trailing price-to-earnings (P/E) ratio of -31.54. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 6.20.
What is the return on equity (ROE) of ELVN?
ELVN has a return on equity (ROE) of -26.64%. Its return on capital employed (ROCE) is -26.04%.
Is ELVN a good stock to buy?
This page provides a data-driven analysis of Enliven Therapeutics, Inc. (ELVN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.